Cargando…

Pelvic Exenteration for Recurrent Endometrial Cancer: A 15-Year Monocentric Retrospective Study

SIMPLE SUMMARY: The incidence of endometrial cancer is continuously rising within the last few decades. The diverse patient population impairs standardized procedures and asks for individualized treatment options. If patients already received or failed to respond to radio- or chemotherapy, secondary...

Descripción completa

Detalles Bibliográficos
Autores principales: Fix, Nando, Classen-von Spee, Sabrina, Baransi, Saher, Luengas-Würzinger, Verónica, Rawert, Friederike, Lippert, Ruth, Mallmann, Peter, Lampe, Björn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571688/
https://www.ncbi.nlm.nih.gov/pubmed/37835424
http://dx.doi.org/10.3390/cancers15194725
_version_ 1785120059735146496
author Fix, Nando
Classen-von Spee, Sabrina
Baransi, Saher
Luengas-Würzinger, Verónica
Rawert, Friederike
Lippert, Ruth
Mallmann, Peter
Lampe, Björn
author_facet Fix, Nando
Classen-von Spee, Sabrina
Baransi, Saher
Luengas-Würzinger, Verónica
Rawert, Friederike
Lippert, Ruth
Mallmann, Peter
Lampe, Björn
author_sort Fix, Nando
collection PubMed
description SIMPLE SUMMARY: The incidence of endometrial cancer is continuously rising within the last few decades. The diverse patient population impairs standardized procedures and asks for individualized treatment options. If patients already received or failed to respond to radio- or chemotherapy, secondary surgical procedures such as pelvic exenteration might be the only curative option. The heterogeneity of the published data is a big challenge for an interpretation of long-term survival after pelvic exenteration. This study retrospectively analyzed data of a homogenous patient population receiving pelvic exenteration. When complete cytoreduction was achieved, a substantial overall survival was measured. Declining morbidity and mortality rates support pelvic exenteration as a valid treatment option for carefully chosen patients with recurrent endometrial cancer. ABSTRACT: Treatment options for recurrent endometrial adenocarcinoma are limited. In those cases, secondary surgical procedures such as pelvic exenteration form the only possible curative approach. The aim of this study was analyzing the outcomes of patients who underwent pelvic exenteration during the treatment of recurrent endometrial cancer intending to identify prognostic factors. More than 300 pelvic exenterations were performed. Fifteen patients were selected that received pelvic exenteration for recurrent endometrial adenocarcinoma. Data regarding patient characteristics, indication for surgery, complete cytoreduction, tumor grading and p53- and L1CAM-expression were collected and statistically evaluated. Univariate Cox regression was performed to identify predictive factors for long-term survival. The mean survival after pelvic exenteration for the whole patient population was 22.7 months, with the longest survival reaching up to 69 months. Overall survival was significantly longer for patients with a curative treatment intention (p = 0.015) and for patients with a well or moderately differentiated adenocarcinoma (p = 0.014). Complete cytoreduction seemed favorable with a mean survival of 32 months in contrast to 10 months when complete cytoreduction was not achieved. Pelvic exenteration is a possible treatment option for a selected group of patients resulting in a mean survival of nearly two years, offering a substantial prognostic improvement.
format Online
Article
Text
id pubmed-10571688
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105716882023-10-14 Pelvic Exenteration for Recurrent Endometrial Cancer: A 15-Year Monocentric Retrospective Study Fix, Nando Classen-von Spee, Sabrina Baransi, Saher Luengas-Würzinger, Verónica Rawert, Friederike Lippert, Ruth Mallmann, Peter Lampe, Björn Cancers (Basel) Article SIMPLE SUMMARY: The incidence of endometrial cancer is continuously rising within the last few decades. The diverse patient population impairs standardized procedures and asks for individualized treatment options. If patients already received or failed to respond to radio- or chemotherapy, secondary surgical procedures such as pelvic exenteration might be the only curative option. The heterogeneity of the published data is a big challenge for an interpretation of long-term survival after pelvic exenteration. This study retrospectively analyzed data of a homogenous patient population receiving pelvic exenteration. When complete cytoreduction was achieved, a substantial overall survival was measured. Declining morbidity and mortality rates support pelvic exenteration as a valid treatment option for carefully chosen patients with recurrent endometrial cancer. ABSTRACT: Treatment options for recurrent endometrial adenocarcinoma are limited. In those cases, secondary surgical procedures such as pelvic exenteration form the only possible curative approach. The aim of this study was analyzing the outcomes of patients who underwent pelvic exenteration during the treatment of recurrent endometrial cancer intending to identify prognostic factors. More than 300 pelvic exenterations were performed. Fifteen patients were selected that received pelvic exenteration for recurrent endometrial adenocarcinoma. Data regarding patient characteristics, indication for surgery, complete cytoreduction, tumor grading and p53- and L1CAM-expression were collected and statistically evaluated. Univariate Cox regression was performed to identify predictive factors for long-term survival. The mean survival after pelvic exenteration for the whole patient population was 22.7 months, with the longest survival reaching up to 69 months. Overall survival was significantly longer for patients with a curative treatment intention (p = 0.015) and for patients with a well or moderately differentiated adenocarcinoma (p = 0.014). Complete cytoreduction seemed favorable with a mean survival of 32 months in contrast to 10 months when complete cytoreduction was not achieved. Pelvic exenteration is a possible treatment option for a selected group of patients resulting in a mean survival of nearly two years, offering a substantial prognostic improvement. MDPI 2023-09-26 /pmc/articles/PMC10571688/ /pubmed/37835424 http://dx.doi.org/10.3390/cancers15194725 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Fix, Nando
Classen-von Spee, Sabrina
Baransi, Saher
Luengas-Würzinger, Verónica
Rawert, Friederike
Lippert, Ruth
Mallmann, Peter
Lampe, Björn
Pelvic Exenteration for Recurrent Endometrial Cancer: A 15-Year Monocentric Retrospective Study
title Pelvic Exenteration for Recurrent Endometrial Cancer: A 15-Year Monocentric Retrospective Study
title_full Pelvic Exenteration for Recurrent Endometrial Cancer: A 15-Year Monocentric Retrospective Study
title_fullStr Pelvic Exenteration for Recurrent Endometrial Cancer: A 15-Year Monocentric Retrospective Study
title_full_unstemmed Pelvic Exenteration for Recurrent Endometrial Cancer: A 15-Year Monocentric Retrospective Study
title_short Pelvic Exenteration for Recurrent Endometrial Cancer: A 15-Year Monocentric Retrospective Study
title_sort pelvic exenteration for recurrent endometrial cancer: a 15-year monocentric retrospective study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571688/
https://www.ncbi.nlm.nih.gov/pubmed/37835424
http://dx.doi.org/10.3390/cancers15194725
work_keys_str_mv AT fixnando pelvicexenterationforrecurrentendometrialcancera15yearmonocentricretrospectivestudy
AT classenvonspeesabrina pelvicexenterationforrecurrentendometrialcancera15yearmonocentricretrospectivestudy
AT baransisaher pelvicexenterationforrecurrentendometrialcancera15yearmonocentricretrospectivestudy
AT luengaswurzingerveronica pelvicexenterationforrecurrentendometrialcancera15yearmonocentricretrospectivestudy
AT rawertfriederike pelvicexenterationforrecurrentendometrialcancera15yearmonocentricretrospectivestudy
AT lippertruth pelvicexenterationforrecurrentendometrialcancera15yearmonocentricretrospectivestudy
AT mallmannpeter pelvicexenterationforrecurrentendometrialcancera15yearmonocentricretrospectivestudy
AT lampebjorn pelvicexenterationforrecurrentendometrialcancera15yearmonocentricretrospectivestudy